Factor Xa inhibitors (DOACs): Pharmacology Made Easy & Relevant

Factor Xa inhibitors (DOACs) made easy—fast, clear, and clinically relevant. In this lecture from This is Why, Dr. Busti will break down direct oral anticoagulants (DOACs) and how Factor Xa inhibitors work, with relevance. You’ll learn how to: What Factor Xa inhibitors do (mechanism of action) Key drugs: Apixaban (Eliquis), Rivaroxaban (Xarelto), Edoxaban (Savaysa) Common indications: Afib stroke prevention, DVT/PE treatment Major adverse effects and safety: bleeding risk, interactions, and monitoring pearls Reversal overview: What to know + when it matters The goal = make medical education easy and clinically relevant. 👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/d... 👉 Get more with a free membership at https://www.thisiswhy.health/ Access free downloads from our videos Access deep dive content from Dr. Busti Organize content via playlists & collections Join live Q&A Receive member newsletters Coupons & discounts for exam prep resources Chapter Table of Contents 00:00 Intro: DOAC Factor Xa Inhibitors Overview 01:57 Which Drugs Count: Apixaban, Rivaroxaban, Edoxaban + Fondaparinux 03:11 Anticoagulant Big Picture: Xa Inhibitors vs Heparins vs Warfarin 05:23 Key Advantages vs Warfarin: Rapid Onset, No Routine INR 07:27 Reversal Landscape: Andexanet Alfa Gone → PCC Strategy 08:07 Core Indications: DVT/PE Treatment & Prophylaxis 09:27 AFib Stroke Prevention: Risk–Benefit (CHA₂DS₂-VASc, HAS-BLED) 11:23 Coagulation Cascade Refresher: Why Factor Xa Matters 13:29 Venous vs Arterial Clots: Anticoagulants vs Antiplatelets 13:58 Fondaparinux vs DOACs: Antithrombin-Dependent vs Direct Xa Inhibition 15:25 Oral vs Parenteral Xa Inhibitors: Structure & Absorption 16:34 Pharmacokinetics: Rapid Effect, Short Half-Life, Adherence 18:54 Drug Interactions: CYP3A4, P-gp, BCRP 21:20 Clinical “Do Not Use”: Mechanical Valves, Triple-Positive APS 23:35 Special Populations: Renal Dysfunction, Elderly, Low Body Weight 26:25 Bleeding Risk, Reversal, and Monitoring (CBC, CMP, LFTs) 34:40 Final Summary & Key Takeaways 👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. 🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #FactorXaInhibitors #DOACs #Anticoagulation #Apixaban #drbusti Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.